TickerTalks
Browse all tickers →
TickerTalks›$LEGN
LELEGN

Legend Biotech Corporation

$LEGN·$3.4B·Biotechnology·Healthcare
$19.88-3.0%YTD-12.6%1Y-42.2%
Mentions · last 7 days
2026-08-20: 6 posts2026-08-21: 4 posts2026-08-22: 1 posts52+2%
Price updated 2d ago·X counts updated 8d ago
LELEGN
$LEGNLegend Biotech Corporation
$19.88-3.02%52 posts+2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $LEGN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-08-26

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Legend Biotech gained 6% on Q2 EPS beat plus J&J handed C-CAR039 back to AbelZeta — the CAR-T franchise is quietly recovering.

Legend Biotech Corporation is the CAR-T therapy developer (Carvykti, partnered with J&J) whose stock has been broken by CAR-T-category doubts but is now setting up as a coiled recovery on the Q2 print and J&J pipeline decision.

  • The Q2 print signals recovery: adjusted EPS $0.09 (Legend gained 6% on the beat as adjusted EPS doubles consensus at $0.12 vs $0.06) — that's a meaningful operational upside for a company that had been running deep losses; Q4 EPS was -$0.17 sequentially, so the trajectory is inflecting positive.
  • The J&J CAR-T signal is nuanced: J&J handed C-CAR039 back to AbelZeta amid an in-vivo CAR-T pivot — that's a specific CAR-T-category signal that Big Pharma is reallocating rather than abandoning; Legend's Carvykti franchise remains intact and continues to be the growth vector.
  • The tape is coiled at low levels: at 24% of the 52-week range, 12% below the 50-day and 10% below the 200-day on 0.51x normal volume with beta 0.39 — a stock consolidating below both moving averages on light volume with unusual bullish options volume (3x normal) plus a long-term buy setup targeting $36/45/60 from a $19.50-21.50 entry is a real technical framework.

The path if this works is the Nov 11 Q3 print delivering another clean beat plus concrete Carvykti prescription-growth commentary, taking the tape past $30. What breaks it is a Carvykti-uptake slip or a fresh CAR-T-category setback signal — Legend is category-levered to Big Pharma sentiment on CAR-T, and any adverse read compresses the multiple.

Agrees with X sentimentThe X bulls have the setup right — LEGN up 20% since a prior call, unusual bullish options volume (3x normal), long-term buy setup targeting $36/45/60 from $19.50-21.50 entry, J&J handing C-CAR039 back to AbelZeta amid in-vivo CAR-T pivot — and mechanics support the coiled turnaround setup.

What to watch: Nov 11 Q3 print (sell-side EPS $0.02) — a clean beat plus concrete Carvykti prescription-growth commentary breaks the coil past $30; a Carvykti-uptake slip or a fresh CAR-T-category setback signal breaks the tape back to $16.

On the calendar: 2026-11-11 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-25

Bullish tone on Legend Biotech. Posters flag LEGN up 20% since a prior call, unusual bullish options volume (3x normal), and a long-term buy setup targeting 36/45/60 from a 19.50-21.50 entry. News that J&J handed C-CAR039 back to AbelZeta amid an in-vivo CAR-T pivot adds context, and one poster's account tags a new high on the LEGN pop.

Read the AI verdict + X sentiment for $LEGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Cell therapy biotech commercializing Carvykti (BCMA CAR-T) for multiple myeloma in partnership with J&J.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $LEGN.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $LEGN

Neutral — Cell therapy biotech commercializing Carvykti (BCMA CAR-T) for multiple myeloma in partnership with J&J; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-24.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-9.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-11.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-24.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
55.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$0.09$0.12-25.0%
Q1 2026May 12, 2026$-0.15$-0.02-650.0%
Q4 2025Mar 10, 2026$-0.08$-0.17+52.9%
Q3 2025Nov 12, 2025$-0.11$-0.13+15.4%
Next earningsWed, Nov 11·consensus EPS $0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$305.1M+56.4%42.3%-16.3%$-0.30$-111.3M
Q4 FY25$306.4M+64.3%59.7%-6.7%$-0.17$-126.6M
Q3 FY25$272.3M+70.0%57.7%-16.0%$-0.21$23.8M
Q2 FY25$255.1M+36.7%61.6%-8.6%$-0.68$-22.3M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.4B$1.4B – $1.5B$0.02-$0.56 – $1.118
FY27$1.8B$1.5B – $1.9B$0.78$0.22 – $1.219
FY28$2.0B$1.8B – $2.4B$1.15$0.97 – $1.398
FY29$2.4B$2.2B – $2.6B$1.20$1.07 – $1.337
FY30$2.8B$2.6B – $3.0B$1.73$1.54 – $1.917

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.17%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-15.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-14.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 178.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.395-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 30Casey Patrick JohnDirector6.0K sh$89KSellJun 25Ying HuangCEO5.6K sh$82KSellMar 25Ying HuangCEO9.9K sh$87K
+ 2 other (1 award · 1 gift) in window

See when $LEGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 33
AI summary

One Reporting filed a Form 3 reporting initial beneficial ownership of LEGN securities. The form establishes the reporting person's baseline ownership position. Form 3 must be filed within 10 days of becoming a director, officer, or 10%-or-greater shareholder. This is an administrative filing that anchors future insider-transaction reporting for LEGN.

424B5Prospectus supplement (offering)Jun 18424B5
AI summary

Legend Biotech (LEGN) priced a follow-on ADS offering of 7,700,000 ADSs at $29.35 per ADS, raising approximately $226 million gross ($212.4 million net). Each ADS represents two ordinary shares. An overallotment option covers an additional 1,155,000 ADSs. Settlement was expected June 23, 2026. This secondary offering provides capital for Legend's CARVYKTI commercial scaling and pipeline programs.

424B5Prospectus supplement (offering)Jun 17424B5
AI summary

Legend Biotech Corporation (Nasdaq: LEGN, foreign private issuer) launched a $225 million preliminary public offering of American Depositary Shares (ADSs) via 424B5 on June 17, 2026, each ADS representing two ordinary shares at $0.0001 par value. The last reported ADS price on June 16, 2026 was $33.38; joint bookrunners are Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities. Underwriters received an option to purchase additional ADSs; final pricing, share count, and use of proceeds were not yet finalized at the preliminary stage. This is active dilution happening now — a $225M equity raise against a ~$3.4B market cap is material and will expand the ADS float upon final pricing.

3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
+ 23 other (13 6-Ks · 7 3s · 1 13G · 1 F-6EF) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More247wallst.com·19d agoLegend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcriptseekingalpha.com·19d agoLegend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus247wallst.com·19d agoLegend Biotech Q2 Earnings Call Highlightsmarketbeat.com·20d agoLegend Biotech (NASDAQ:LEGN) Shares Gap Down After Analyst Downgradedefenseworld.net·34d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport